The Australia MedTech market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.03% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 8.0 Billion |
Market Forecast in 2032
|
US$ 13.5 Billion |
Market Growth Rate (2024-2032) | 6.03% |
MedTech refers to products, services, or solutions that utilize medical technology for preventing, diagnosing, monitoring, and treating diseases. It includes numerous types, such as telehealth, EMR and HER, medical apps, healthcare analytics, medical wearables, etc. MedTech devices assist healthcare providers in disease diagnosis and treatment procedures with higher accuracy, accessing health records, preparing a diagnosis history, eliminating the need for duplicate tests, and saving total healthcare expenditures. Owing to this, they are widely used across the healthcare sector for several clinical and non-clinical applications.
The high prevalence of numerous chronic diseases along with the escalating demand for advanced healthcare services is primarily driving the Australia MedTech market. In addition to this, the increasing utilization of innovative digital solutions, including healthcare apps and wearable devices, that enable patients to self-monitor heart rate, glucose, blood pressure, etc., is further augmenting the growth of the market. Moreover, the elevating requirement for mobile health (m-Health) services that assist in call conferencing and live consultation features with healthcare professionals is also stimulating the regional market. Besides this, the emerging popularity of MedTech services due to the sudden outbreak of coronavirus infection (COVID-19) for disease management, remote patient monitoring, providing feedback, and suggesting adequate medication is positively impacting the market growth. Furthermore, the growing adoption of personalized treatment options and point-of-care (POC) testing solutions is creating a positive outlook for the Australia market. Additionally, the introduction of favorable policies by the Australian government, such as extending medicare reimbursement to cover remote consultations for encouraging the use of digital health solutions, is acting as another growth-inducing factor. Apart from this, several key players are making significant investments in AI in Healthcare technologies which offer greater precision, ensure proper storage and monitoring of patient information, and enhance the overall user experience. This, in confluence with continuous digital innovations, such as the introduction of robotic surgery units, 3D printing, portable ultrasound, digital tomosynthesis, etc., is anticipated to drive the Australia MedTech market in the coming years.
IMARC Group provides an analysis of the key trends in each segment of the Australia MedTech market report, along with forecasts at the country level from 2024-2032. Our report has categorized the market based on type, component, deployment type, application, and end user.
Breakup by Type:
Breakup by Component:
Breakup by Deployment Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Alcidion Group Limited, Anatomics Pty Ltd, Artrya, AusBiotech, Avanade Australia (Accenture), Cochlear Limited, Ellex, ResMed Inc., Schott AG, and Sirtex Medical Limited.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Billion |
Segment Coverage | Type, Component, Deployment Type, Application, End User, Region |
Regions Covered | Western Australia, New South Wales, Queensland, Victoria, and Rest of Australia |
Companies Covered | Alcidion Group Limited, Anatomics Pty Ltd, Artrya, AusBiotech, Avanade Australia (Accenture), Cochlear Limited, Ellex, ResMed Inc., Schott AG, and Sirtex Medical Limited |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |